5d 1m 3m 1y 5y 10y
PR Newswire (Apr 4, 2014)
PR Newswire (Apr 3, 2014)
at CNBC.com (Apr 2, 2014)
PR Newswire (Apr 1, 2014)
at CNBC.com (Mar 28, 2014)
at CNBC.com (Mar 25, 2014)
at CNBC.com (Mar 24, 2014)
at MarketWatch.com (Mar 21, 2014)
at MarketWatch.com (Mar 21, 2014)
at CNBC.com (Mar 14, 2014)
at CNBC.com (Mar 12, 2014)
at MarketWatch.com (Mar 10, 2014)
at CNBC.com (Mar 4, 2014)
REGN vs. ETF Alternatives
Monday, Mar 247:27 PM
Monday, Mar 247:27 PM| 30 Comments
- As U.S. corporations sit on $1T-plus in cash and with many facing organic growth challenges, Morgan Stanley lists 44 multi-billion dollar cap companies it thinks have a high likelihood of receiving at least one tender offer over the next 12 months.
- In the energy sector: NFX, SD, TDW.
- In materials: CLF, AXLL, UFS, RGLD.
- Consumer discretionary: SBGI, WEN, TPX, EAT, BYI, DWA, JCP, AEO.
- Consumer staples: INGR, HAIN, HSH, WWAV.
- Health care: CELG, ESRX, WLP, REGN, ALXN, AET, CI, BDX, CERN.
- Financial: NSM.
- Tech: BRCD, ONNN, TIBX, SPWR, IM, JBL, SUNE, TER, ARRS, NSR.
- Telecom: CCI, SBAC, LVLT, WIN, FTR.
Friday, Mar 74:24 PM
Friday, Mar 74:24 PM| 5 Comments
- The FDA requests that Regeneron (REGN) and Sanofi (SNY) assess potential neurocognitive side effects of their late stage cholesterol drug alirocumab, a PCSK9 inhibitor.
- Memory loss, impaired concentration and paranoia, though rare, have been associated with the use of statins for lowering LDL cholesterol.
- Both firms disclosed in their regulatory filings that the appearance of these side effects could delay or stop the product's development.
- Pfizer (PFE) and Amgen (AMGN) are also working on PCSK9 inhibitors.
Monday, Mar 310:20 AM
Monday, Mar 310:20 AM| 1 Comment
- Bayer (BAYRY) has filed for Japanese approval of Regeneron's (REGN) Eylea therapy for treating patients with diabetic macular edema, the companies have said. Bayer has the rights to sell Eyelea outside the U.S.
- The submission is based on Phase 3 clinical trials that proved a statistically significant improvement in best-corrected visual acuity from baseline at 52 weeks compared with laser photcoagulation.
- The companies didn't provide a timetable for marketing approval, although the process is usually slower than with the FDA in the U.S. (PR)
Friday, Feb 287:37 AM
Friday, Feb 287:37 AM| 1 Comment
- Bayer believes that Xarelto (blood thinner) and Eylea (eye), which is developed by Regeneron (REGN), will hit peak revenues in 5-6 years. Bayer holds the license to sell Eylea outside the U.S.
- Bayer has increased its combined peak annual sales forecast for its five most important drugs - Adempas (lung), Stivarga (cancer) and Xofigo (cancer), as well as Eylea and Xarelto - to at least €7.5B from a prior forecast of €5.5B. The treatments generated sales of €1.52B in 2013.
- See Bayer's earnings
Monday, Feb 249:18 AM
Monday, Feb 249:18 AM| 1 Comment
- The FDA has accepted Regeneron's (REGN +3.3%) application to expand the use of its Eylea therapy to treat Macular Edema Following Branch Retinal Vein Occlusion, a common vascular disease among the elderly that is caused by a blockage of one of the small veins that carry blood away from the retina.
- Regeneron's application follows a successful Phase III trial.
- Eylea has already been authorized for other indications, including wet age-related macular edema.
Tuesday, Feb 114:48 PM
Tuesday, Feb 114:48 PM| Comment!
- Regeneron's (REGN) 7.4% gain topped today's S&P leader board following Q4 earnings which featured good news on the company’s blockbuster-to-be, Eylea.
- Q4 U.S. sales of the sight-saving drug rose 46% Y/Y to $402M, and REGN forecasts U.S. sales to reach $1.7B-$1.8B this year as it expects the drug to win approval for newer uses.
- RBC Capital thinks Eylea sales could be better than forecast, given that management is typically viewed as conservative when it comes to guidance.
- Brean Capital raises its price on shares to $380 from $367, as it looks to several Phase 3 trials for alirocumab - part of a new class of injectable cholesterol medicines - reading out around mid-2014; the firm views the drug as the next major value driver.
Tuesday, Feb 117:29 AM
Tuesday, Feb 117:29 AM| 6 Comments
- Regeneron (REGN +2%) net profit -79% to $97M, due to a non-cash tax benefit of $336M in Q4 2012, an income tax provision in 2013, and higher operating costs last year.
- Eylea net U.S. sales $402M vs $276M a year earlier; international $184M vs $19M.
- Cash position: $1.08B at end of 2013 vs $588M.
- Forecasts 2014 Eylea net product sales of $1.7-1.8B in U.S. vs. $1.41B in 2013.
- Expects Eylea to continue growing "through demographic and geographic expansion," as well as via potential approvals in new indications. (PR)
Tuesday, Feb 116:31 AM|Tuesday, Feb 116:31 AM| Comment!
Tuesday, Feb 1112:05 AM
Monday, Feb 105:30 PM
Monday, Feb 108:16 AM
Monday, Feb 108:16 AM| 1 Comment
- Regeneron's (REGN +3.15%) Eylea treatment improved vision and maintained that improvement over two years in a Phase III trial of patients with diabetic macular edema (DME).
- DME is a leading cause of blindness in younger and middle-aged adults; Eylea could potentially treat over 6M sufferers globally.
- Regeneron and partner Bayer (BAYRY) are waiting for U.S. and EU approval of Eylea to treat DME; the therapy has already been authorized for other indications, including wet age-related macular edema. (PR)
Wednesday, Jan 159:55 AM
Wednesday, Jan 159:55 AM| Comment!
- Shares of Regeneron (REGN -4.4%) are pulling back after a big run Tuesday.
- BMO has downgraded the stock to Market Perform from Outperform.
- Price target is unchanged at $331.
- See also: Roth upbeat on REGN amid new Bayer deal, genetics initiative
Tuesday, Jan 1412:43 PM
Tuesday, Jan 1412:43 PM| 3 Comments
- Roth Capital is out with a bullish note on Regeneron (REGN +9.1%) on the heels of the company's announcement of a new development agreement with Bayer.
- Here's analyst Joseph Pantginis, commenting: "Preclinical studies have suggested that blocking both PDGFR-beta and vascular endothelial growth factor (VEGF) can provide additional benefit over anti-VEGF treatment (such as EYLEA) alone in wet AMD."
- Buy rating maintained.
- Price target is $362.
- In other company news, REGN has announced a collaboration with Geisinger Health System under which the companies will "study the genetic determinants of human disease." Additionally, Sanofi (SNY) has amended its investor agreement with REGN and retains the right to "acquire up to 30% of REGN's outstanding common stock and Class A stock [while gaining] the right to nominate a single independent director to the Regeneron Board of Directors upon reaching 20% ownership [stake]."
Tuesday, Jan 147:40 AM
Tuesday, Jan 147:40 AM| Comment!
- Regeneron Pharmaceuticals (REGN) and Bayer (BAYZF) are deepening their relationship with a plan develop a new therapy for wet age-related macular degeneration.
- Bayer will make an upfront payment of $25.5M to Regeneron and up to $40M in options and milestone payments, and it will pay royalties on any product sales outside the U.S.
- Regeneron will retain 100% of U.S. profits.
- Human clinical studies are planned for early this year. (PR)
Thursday, Jan 21:54 PM
Thursday, Jan 21:54 PM| Comment!
- IQWiG, Germany's cost gatekeeper, struck a blow to Regeneron (REGN -0.5%) and Bayer's (BAYZF -4.1%) Eylea Thursday, saying it could not determine whether the drug is superior to Lucentis (NVS -2.1%) in treating macular edema.
- As Reuters notes, the institute's position "could affect the level of reimbursement by public insurers for Eylea in Germany."
Wednesday, Dec 182013, 7:46 AM